Please assess the completion status of the following clinical trial:

Trial Title: COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must have read, understood, and signed the informed consent form (ICF).~2. Participants of either gender aged 12 years and older at screening.~3. Medically stable~4. Must be able to attend all visits of the study and comply with all study procedures,~5. Women of childbearing potential (WOCBP) must be able and willing to use at least 1 highly effective method of contraception for a minimum of 3 months after the last dose of study vaccine.~6. WOCBPs must have a negative pregnancy test prior to each vaccination.~Exclusion Criteria:~1. Participant is pregnant or planning to become pregnant within 3 months after study vaccine administration.~2. History of allergy to any component of the vaccine.~3. Significant infection (e.g. positive SARS-CoV-2 RT-PCR) or other acute illness, including fever \> 100 °F (\> 37.8 °C) 48 hours before vaccination.~4. Participant has a known or suspected defect of the immune system~5. Participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome.~6. Participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. A history of hematologic malignancy is a permanent exclusion. Participants with a history of skin cancer must not be vaccinated at the previous tumour site.~7. History of drug dependency or current use of drug of abuse or alcohol abuse at screening.~8. Significant blood loss (\> 450 mL) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (Visit 1).~9. History of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following IM injections or venepuncture.~10. Severe and uncontrolled ongoing autoimmune or inflammatory disease History of Guillain-Barre syndrome or any other demyelinating condition.~11. Any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer~    Prior/concomitant therapy:~12. Receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study.~13. Receipt of medications and or vaccinations intended to prevent COVID-19.~14. Receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (Visit 1).~15. Any member of the study team or sponsor.~16. An immediate family member or household member of the study's personnel.~Booster Vaccination (Adults and Adolescents)~In addition to the above-described eligibility criteria, the following criteria must be met:~1. Participant has not received another licensed COVID-19 vaccine during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VLA2001 (Type: EXPERIMENTAL): \<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222
- AZD1222 (Type: ACTIVE_COMPARATOR): \<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222
- VLA2001 - adolescent part (Type: EXPERIMENTAL): ≥12 to \< 18 years will be randomized 1:1 to receive VLA2001 or Placebo
- Placebo (Type: PLACEBO_COMPARATOR): ≥12 to \< 18 years will be randomized 1:1 to receive VLA2001 or Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).